Sclerosing cholangitis in the era of target chemotherapy: A possible anti-VEGF effect

Delis, Spiros; Triantopoulou, C.; Bakoyiannis, Andreas; Tassopoulos, Nikos; Athanasiou, Kostas; Dervenis, Christos

doi:10.1016/j.dld.2007.11.016

Cited by 13 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential pathogenic role of angiogenesis has been shown in the contextofviralhepatitis,autoimmune hepatitis, PBC, and hepatocellular carcinoma (30). A study described the use of bevacizumab (a monoclonal antibody to VEGF) in a case of secondary sclerosing cholangitis in a patient with liver metastases treated by bevacizumab in a neoadjuvant setting with liver resection (31). VEGF overexpression in liver and mesentery has been demonstrated in liver biopsies from patients with HCV-associated cirrhosis or liver tissues removed during transplantation (32).…”

Section: Discussionmentioning

confidence: 99%

Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR‐200b down‐regulation

Meng

Zhou

et al. 2017

FASEB j.

View full text Add to dashboard Cite

Melatonin therapy or prolonged exposure to complete darkness reduces biliary hyperplasia and liver fibrosis in bile-duct-ligated (BDL) rats; however, no information exists in primary sclerosing cholangitis (PSC). Thus, we aimed to determine the therapeutic effects of prolonged dark therapy or melatonin administration on hepatic fibrosis in the multidrug resistance gene 2-knockout (Mdr2) mouse model of PSC. Melatonin levels, biliary mass, liver fibrosis, angiogenesis and miR-200b expression were evaluated in wild-type and Mdr2 mice exposed to darkness or melatonin treatment or in male patients with PSC and healthy controls. Mdr2 mice were also treated with miR-200b inhibitor or control before evaluating biliary mass, liver fibrosis, and angiogenesis. After overexpression of arylalkylamine -acetyltransferase (AANAT; the enzyme regulating melatonin synthesis) or inhibition of miR-200b in cholangiocytes and hepatic stellate cells, we evaluated angiogenesis and fibrosis gene expression. After exposure to darkness or administration of melatonin, Mdr2 mice show elevated serum melatonin levels and inhibition of biliary mass, along with reduction of liver fibrosis and angiogenesis. MicroRNA PCR analysis demonstrated that miR-200b expression increased in Mdr2 mice and patients with PSC compared with controls and decreased in Mdr2 mice subjected to dark exposure or melatonin treatment. Inhibition of miR-200b in Mdr2 ablates biliary proliferation, liver fibrosis, and angiogenesis. , overexpression of AANAT or inhibition of miR-200b in cholangiocytes and hepatic stellate cells decreased the expression of miR-200b, angiogenesis, and fibrosis genes. Dark therapy or targeting melatonin/miR-200b axis may be important in the management of biliary damage and liver fibrosis in cholangiopathies including PSC.-Wu, N., Meng, F., Zhou, T., Han, Y., Kennedy, L., Venter, J., Francis, H., DeMorrow, S., Onori, P., Invernizzi, P., Bernuzzi, F., Mancinelli, R., Gaudio, E., Franchitto, A., Glaser, S., Alpini G. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR‐200b down‐regulation

Meng

Zhou

et al. 2017

FASEB j.

View full text Add to dashboard Cite

show abstract

“…Cholangitis similarly developed after cessation of nivolumab in one previous case (10). It has been reported that treatment with the anti-angiogenic agent bevacizumab caused sclerosing cholangitis in a patient with colorectal carcinoma after surgical treatment of liver metastases (13). Ischemia may be induced by prothrombotic antibody-mediated clot formation in the vessels supplying the bile ducts (14).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis

et al. 2019

View full text Add to dashboard Cite

Immunotherapy targeting programmed cell death-1 (PD-1) signaling is becoming the standard of care for advanced gastric cancer. We herein report a patient with gastric adenocarcinoma with peritoneal dissemination who was treated with nab-paclitaxel and ramucirumab following nivolumab and developed sclerosing cholangitis. Endoscopic retrograde cholangiography showed irregular narrowing and widening of the entire intrahepatic biliary system. Intriguingly, the patient receiving second-line chemotherapy with nab-paclitaxel plus ramucirumab prior to being administered nivolumab, however, he had experienced progressive disease. Thereafter, the administration of fourth-line chemotherapy with nab-paclitaxel and ramucirumab following nivolumab resulted in a clinical response. Nivolumab may enhance the efficacy of the subsequent chemotherapy regimens but also induce sclerosing cholangitis.

show abstract

“…4–6 There have so far been 4 case reports of CISC triggered by systemic chemotherapy, 3 of which have been reported from Japan, although it remains unclear whether races and ethnic groups have some relationship with the development of CISC. 7–10 In addition to fluoropyrimidines, other drugs, such as taxanes and bevacizumab, have been suggested to be causative drugs. 7–10 In this patient, CISC is considered to have been triggered by taxane and/or bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

“…4–6 In contrast, there have been only a few case reports of CISC triggered by systemic chemotherapy. 7–10 We report a rare case of CISC caused by systemic chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy

et al. 2019

View full text Add to dashboard Cite

A 61-year-old woman diagnosed with cervical cancer received systemic chemotherapy using paclitaxel and bevacizumab. Marked elevation of liver enzyme levels was observed. Ultrasonography and computed tomography showed wall thickening of the extrahepatic and intrahepatic bile ducts accompanied by stricture and dilatation. According to these, she was diagnosed as chemotherapy-induced sclerosing cholangitis (CISC), a form of secondary sclerosing cholangitis. Although CISC triggered by systemic chemotherapy is rare, CISC should be considered as a clinically important adverse event of chemotherapy because it causes rapid deterioration of liver function and necessitates interruption of chemotherapy.

show abstract

Sclerosing cholangitis in the era of target chemotherapy: A possible anti-VEGF effect

Cited by 13 publications

References 12 publications

Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR‐200b down‐regulation

Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR‐200b down‐regulation

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis

Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy

Contact Info

Product

Resources

About